Sandeep Khurana, MD
Cardiovascular Disease · Grandville, MINPI 1720063787
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,184 of the $79,705 with a category attached, or 71.7%. 26 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 47.1% of the total. Reporting peaked in 2019 at $49,779 and has fallen 94.1% since, to $2,919 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $296.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$38K
- Esperion Therapeutics, Inc.$16K
- Amgen$7K
- Regeneron Healthcare Solutions, Inc.$5K
- Bayer$4K
- CSL Behring$3K
- plus $9K from 20 others
Across 377 payments — averaging $5791.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.6M
- Novartis$157K
- Boehringer Ingelheim$114K
- Regeneron$104K
- Esperion Therapeutics, Inc.$81K
- Boehringer Ingelheim International GmbH$30K
- plus $49K from 4 others
What the payments were for
- Consulting fees$2,0323%
- Speaking & faculty fees$57,18472%
- Travel & lodging$9,40912%
- Food & beverage$10,76614%
- Education$3150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 29 | $37,546 |
| Esperion Therapeutics, Inc. | 15 | $16,146 |
| Amgen | 41 | $6,642 |
| Regeneron Healthcare Solutions, Inc. | 11 | $4,585 |
| Bayer | 19 | $3,559 |
| CSL Behring | 13 | $2,585 |
| Boehringer Ingelheim | 14 | $1,750 |
| Novo Nordisk | 22 | $1,515 |
| Merck | 8 | $1,406 |
| Novartis | 13 | $1,263 |
| Pfizer | 21 | $854 |
| Amarin Pharma, Inc. | 39 | $403 |
| Alnylam Pharmaceuticals Inc. | 3 | $320 |
| AstraZeneca | 4 | $283 |
| Cequr Corporation | 1 | $201 |
| Xeris Pharmaceuticals, Inc. | 3 | $182 |
| Lilly USA, LLC | 1 | $109 |
| Bridgebio Pharma, Inc. | 1 | $109 |
| Dexcom, Inc. | 2 | $81 |
| Kestra Medical Technology Services, Inc. | 1 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Preventice Services, LLC | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,705 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 147 | $169,597 |
| JardianceEmpagliflozin | 123 | $147,971 |
| OzempicSemaglutide | 37 | $62,014 |
| EliquisApixaban | 60 | $57,790 |
| Repatha SureclickEvolocumab | 73 | $56,580 |
| MounjaroTirzepatide | 33 | $54,856 |
| XareltoRivaroxaban | 31 | $35,707 |
| EntrestoSacubitril/Valsartan | 19 | $34,358 |
| TrulicityDulaglutide | 21 | $21,258 |
| Ezetimibe | 334 | $10,289 |
| Rosuvastatin Calcium | 197 | $4,811 |
| Metformin Hcl ErMetformin Hcl | 187 | $4,782 |
| Pitavastatin Calcium | 16 | $4,266 |
| Atorvastatin Calcium | 190 | $4,029 |
| Icosapent Ethyl | 14 | $2,425 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $283 | $169,597147 claims |
| Boehringer IngelheimJardiance | $1,750 | $147,971123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $109 | $76,11454 claims |
| Novo NordiskOzempic | $1,515 | $62,01437 claims |
| PfizerEliquis | $854 | $57,79060 claims |
| Johnson & JohnsonXarelto | $19 | $35,70731 claims |
| NovartisEntresto | $1,263 | $34,35819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Grandville
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
- Douglas HorstmanshofRoyal Oak$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.